NURIX THERAPEUTICS INC reports a Return on Equity (ROE) of -61.40%.

What is NRIX's dividend yield?

NURIX THERAPEUTICS INC offers a dividend yield of 0.00%.

What is NRIX's Deepscope Quality Score?

Deepscope rates NRIX's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy NRIX?

Deepscope's AI Timing Score for NRIX is 51 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does NRIX belong to?

NURIX THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

NRIX (NASDAQ) 株価分析 | NURIX THERAPEUTICS INC

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-12 | FS: 2026-02-28)

NRIX

NURIX THERAPEUTICS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 76

USD 16.95

-0.03 (-0.18%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-61.4%

ROE

-46.4%

ROA

0.00%

Div Yield

NURIX THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 16.95 Price -0.03 (-0.18%) Day Change	NEWS SCORE: 76

NRIX, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...

Deepscope 分析

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	76
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	16.95
PBV / Sector	3.65 / 4.91
Earning Per Share	-2.85

PE / Sector	N/A / 18.34
PEG or PE/Growth / Sector	N/A / 0.61
Average 1M Daily Value	44.02 M GREAT
Average 1W Daily Value	116.39 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-411.37 / 468.85
NPM Average (%) / Sector	-339.60 / -1,531.69
NPM Change Average (%) / Sector	13.16 / 5,028.65 GOOD
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-46.42 / 31.69
ROA Average (%) / Sector	-38.82 / -353.18
ROA Change Average (%) / Sector	6.68 / 5,214.65
ROE (%) / Sector	-61.40 / 10.58
ROE Average (%) / Sector	-54.74 / 27.64
ROE Change Average (%) / Sector	10.30 / 2,048.88 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 5.15

登録情報

Analyze Date	2026-06-13 11:13:36
Symbol	NRIX
Name	NURIX THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	103.41 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,755.83 / 9,034.83

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1600 Sierra Point Parkway, Brisbane, CA, United States, 94005

Phone: 415 660 5320

Website: https://www.nurixtx.com

Employees: 317

Sector: Healthcare >> Biotechnology

Description: Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.